Parkinson's disease (PD) is the second most common neuro- 
Introduction
disorders, autonomic dysfunctions, olfactory deficits, and neuropsychiatric symptoms particularly depression, anxiety and apathy [2, 5] . Anxiety is frequently reported in more than 50% of PD patients [6] . In general, all types of anxiety disorders found in PD are associated with generalized anxiety disorder, agoraphobia, specific phobia, and social anxiety disorder, panic disorder, and obsessive-compulsive disorder or related disorders (according to DSM-V) [7, 8] . Anxiety disorder, in some patients, is a "reactive" response to the diagnosis of PD, as a result of stress and motor disability [9] . However, PD patients have greater risks developing anxiety before the diagnosis of PD [5, 10] . In addition, loss of striatal serotonin [11] , dopamine and noradrenaline [12] innervation are present in living patients with PD. Therefore, these evidence suggest that anxiety is an early non-motor symptom in Parkinson's disease [13] .
Moreover, another non-motor alteration that aggravates anxiety, in humans, and consequently PD, is rapid eye movement (REM) sleep loss [3] . Furthermore, REM sleep deprivation (REMSD) is known to increase anxiety behaviors in humans [14] . While preclinical studies, in rodents, are still inconsistent, suggesting that REMSD triggers anxiolytic-like [15] [16] [17] or anxiogenic-like effects [18] [19] [20] . These lack of consistency difficult translational applicability of preclinical data of anxiety and sleep deprivation [21] .
The research of the motor and non-motor disturbances of PD frequently adopts a number of animal models based on neurotoxins injected within the brain. Rotenone is a pesticide which, freely crosses cellular membranes and accumulates in subcellular organelles such as mitochondria, where inhibits the mitochondrial complex Ι of electrical transport chain, in this way inducing apoptosis of the nigrostriatal pathway [22, 23] . This dopaminergic neuronal loss mimics several motor [23] and non-motor features of PD, such as olfactory dysfunction [24] and depression [25, 26] . However, studies reporting anxiety-like behaviors and their consequences after REMSD, in neurotoxin-based models, are sparse and somewhat inconsistent [6, 27] . It is worth mentioning, that only one study, according to our knowledge, demonstrated the effects of rotenone in anxiety-like behaviors, after intraperitoneal injections of this neurotoxin [28] .
There is a growing interest in exploring novel pharmacotherapeutic strategies for anxiety in the context of PD [13, 26, 29] . Among these emerging targets, melatoninergic drugs have gained considerable attention. Several reports have demonstrated anxiolytic-like effects of melatonin, observed in the elevated plus maze test (EPM) by an increase in the number of entries and time spent into the open arms [30] [31] [32] . The main roles of this neuropeptide are related to the control of the circadian sleep-wake states, regulation of sleep and seasonal biorhythm [33] [34] [35] by activating MT1 and MT2 receptors, two G-protein-coupled membrane receptors [36] .
It has been hypothesized that dysregulations of these melatonin receptors may be involved in the installation of mood disorders [37] . As a matter of fact, it has been demonstrated that MT2 receptors play an important role in depression [38] as well as in anxiety [39] . Activation of MT2 receptors, by the partial agonist UCM765, elicits an anxiolytic-like effect in rats [39] . However, it is still unexplained if this effect is also observed in the intranigral rotenone model of PD. Besides, it remains to be clarified if striatal MT2 receptors could elicit anxiety-like effects, since these receptors are present within the striatum [40, 41] . Hence, we hypothesize that striatal MT2 receptors associated to dopamine depletion might be implicated in the pathogenesis of anxiety in PD [42, 43] . Therefore, in the present study we sought to investigate the existence of a purportedly anxiolytic-like effect generated by the striatal MT2 activation, achieved by the infusion of a selective agonist 8-methoxy-2-propionamidotetralin (8-M-PDOT), and counteracted by the selective antagonist 4-phenyl-2-propionamidotetralin (4-P-PDOT), after dopaminergic degeneration, induced by intranigral rotenone. This hypothesis was tested under the PD model and the REMSD protocol.
2.
Material and methods
Ethics statement
The studies were carried out in accordance with the guidelines of the Committee on the Care and Use of Laboratory Animals, United States National Institutes of Health. In addition, the protocol complies with the recommendations of Federal University of Paraná and was approved by the Institutional Ethics Committee (approval ID # 695).
Animals
Male Wistar rats from our breeding colony were used, weighing 280-320 g at the beginning of the experiments. The animals were housed in groups of five, in polypropylene cages and maintained under standard conditions of temperature (2272 1C) and illumination (12/12 h light-dark cycle). The animals had free access to water and food throughout the experiment.
Drugs
Xylazine and ketamine were purchased from Syntec (Brazil). Rotenone was dissolved in dimethylsulfoxide (DMSO) at a final concentration of 12 mg/mL, both drugs were purchased by Sigma-Aldrich (United States). This solution was administered by bilateral intranigral injections through stereotaxic surgery. The selective MT2 agonist 8-methoxy-2-propionamidotetralin (8-M-PDOT) and the selective MT2 antagonist 4-phenyl-2-propionamidotetralin (4-P-PDOT) were purchased from TOCRIS (San Diego, CA, USA), and were dissolved with DMSO. The final concentrations were 10 mg/mL and 5 mg/mL, respectively, which were injected into the striatum, through bilateral cannulas also positioned by stereotaxic surgery. The vehicle group was injected with DMSO.
Experimental design
In the present study, the rats were randomly distributed into two groups named sham and rotenone. Seven days after the stereotaxic surgery ( 
Stereotaxic surgery
Rats were sedated with intraperitoneal xylazine (10 mg/kg) and anaesthetized with intraperitoneal ketamine (90 mg/kg).
The following coordinates were used (having the bregma as a reference) to allow the bilateral nigral lesion with rotenone: SNpc (AP)¼ À5.0 mm, (ML)¼ 72.1 mm and (DV)¼ À8.0 mm [44] . Needles were guided to the region of interest for a bilateral infusion of 1 mL of rotenone (12 mg/mL) using an electronic infusion pump (Insight Instruments, Ribeirão Preto, Brazil) at a rate of 0.33 mL/min for 3 min [45] [46] [47] . Sham operations followed the same procedure, but 1 mL of DMSO was injected instead. Complementarily, bilateral guide cannulas were implanted in the dorsal striatum of each rat allowing a subsequent infusion 1 mL of 8-M-PDOT (10 mg/mL), 4-P-PDOT (5 mg/mL) or vehicle (DMSO) at a rate of 0.33 mL/min for 3 min, in their respective groups. Coordinates with reference to bregma for implantation of guide cannulas were: AP¼ À1.0 mm, ML¼73.0 mm and DV¼ À6.0 mm [44] . This administration protocol was performed during the light-cycle between 7:00 a.m. and 9:00 a.m.
REMSD procedure
REMSD was attained by means of the single platform method. Rats were individually placed on a circular platform (6.5 cm in diameter) in a cage (23 cm Â 23 cm Â 30 cm) filled with water up to 1 cm below the platform level. At the onset of each REM sleep episode, the animal experiences a loss of muscle tonus and falls into the water, thus being awakened. When platforms of this size are used, REM sleep is completely eliminated [48] . Throughout the study, the experimental room was maintained at controlled conditions (2272 1C, 12/12 h light/ dark cycle, lights on 7:00 a.m. and off on 7:00 p.m.). The control group was kept in the same room as the REMSD rats during the study. Food and water were provided ad libitum by placing chow pellets in a dispenser positioned inside the cage and water bottles on a grid located on top of the tank.
Elevated plus maze test
The elevated plus maze apparatus was made of wood, and consisted in two opposite open-arms (50 cm Â 10 cm), and two enclosed-arms (50 cm Â 10 cm Â 40 cm). The whole apparatus was elevated 50 cm above the floor. The rats were placed on the central platform (10 cm Â 10 cm) facing one of the enclosed arms. 
Open-field test
The apparatus consists of a circular arena (1 m of diameter) limited by a 40 cm high wall and illuminated by four 60 W lamps situated 48 cm above the arena floor, providing illumination around 300 lx. The animals were gently placed in the center of the arena and were allowed to freely explore the area for 5 min. During the experiments, the open-field was video recorded, and the measures of total distance were computed online by an image analyzer system (Smart junior, PanLab, Harvard Apparatus, Spain).
Statistical analysis
Differences between the groups in the elevated plus maze and open-field test were analyzed by one-way analysis of variance (ANOVA) followed by the Neuman-Keuls post hoc test. Values are expresses as mean7standard error of mean (SEM). The level of significance was set at Pr 0.05. At this point a note of caution should be added: the analysis of the groups could also be performed by a two-way ANOVA, however, our sample size has prevented us to perform it.
Results
The anxiety-like effects of 8-M-PDOT and 4-P-PDOT treatment, in the EPM are shown in Fig. 2 . The sham control 8-M-PDOT (Fig. 3B) [F(7,90)¼1.607, P¼ 0.1448]. Once more, the comparisons between treatments of the rotenone groups (Fig. 3C) , considering this parameter, demonstrated an increased locomotion in the rotenone control 4-P-PDOT group (Po0.01) compared to the rotenone control 8-M-PDOT group. Additionally, the rotenone REMSD 8-M-PDOT group demonstrated a locomotion increment (Po0.01) compared to the rotenone REMSD 4-P-PDOT group [F(3,38)¼12.38, Po0.001].
Discussion
The activation of striatal MT2 receptors by the selective agonist 8-M-PDOT triggered an anxiolytic-like effect, demon- arms. This effect was blocked by the selective MT2 receptor antagonist, 4-P-PDOT [39] . Thus, anxiolytic-like effect is purportedly associated to MT2 activation. Notwithstanding, in our study we focused on the role of striatal MT2 receptors hence, we investigated if after a dopaminergic degeneration, induced by intranigral rotenone, the administration of MT2 agonist or antagonist would reduce the anxiogenic-like effect of rotenone. In fact, rotenone did not increase the anxietylike behavior, however this neurotoxin was able to prevent the anxiolytic-like effect promoted by 8-M-PDOT. Another important consideration relies on the time of MT2 drugs infusion (between 7:00 a.m. and 9:00 a.m.), which is nadir of melatonergic blood levels. Conversely, it is demonstrated that melatonin receptors, in the striatum, did not suffer diurnal variations [49] . Furthermore, it is important to state that our rationale is strictly based on pharmacological activation/ blockade of the receptors and not necessarily influenced by the physiological melatonin blood, or brain levels.
Another important finding in this study is that REMSD was able to induce remarkable anxiolytic-like effects similar to 8-M-PDOT. This outcome becomes evident due to the ceiling effect induced by REMSD (Fig. 2E) . However, these results cannot be interpreted as a merely consequence of an alteration in locomotion inflicted by REMSD, since REMSD itself did not appear to produce motor changes. Nonetheless, locomotor adjustments occurred only in the presence of a dopaminergic lesion induced by rotenone. In fact, striatal MT2 blockade produced an increased locomotion not replicated in the context of REMSD. Also, MT2 activation appeared to generate a prevalent locomotor increase compared to MT2 blockade. This result could also be interpreted as a possible anxiogenic effect or even a mania-like effect [50] , probably caused by REMSD. Indeed, REMSD is known to cause hyperactivity as a result of dopaminergic supersensitivity [51] , and is also considered as a model of mania [50] . Many studies describe anxiolytic-like effects as consequence of insufficient sleep [15] [16] [17] . Meanwhile, anxiogenic-like effects are also reported in animal studies [18] [19] [20] . One possible explanation for this discrepancy is due to the variations in the REMSD protocols and different behavioral tests employed to access anxiety [52] .
The intranigral infusion of rotenone did not induce an anxiogenic-like effect, suggesting that this neurotoxin, or perhaps our protocol (or both), presented limitations in mimicking anxiety-like alterations such as observed in PD. Rotenone is a classical inhibitor of the mitochondrial complex I of the electron transport chain, hence, inducing apoptosis mechanisms of dopaminergic neurons very similarly to PD [2] . That is, lipid peroxidation, changes in the mitochondrial membrane potential, caspase-3 activation and DNA fragmentation [53] . In fact, 40-80% of striatal dopamine depletion can be observed after intranigral administration of rotenone [46, 54, 55] , while serotoninergic neurons is not affected by this neurotoxin [54] .
The use of rotenone as a PD model is gaining growing attention particularly in light of non-motor disturbances like REM sleep behavior disorder [56] . Further, this neurotoxin mimics olfactory dysfunction [24] and depression [25, 26] which are pathophysiological conditions with a strong dopaminergic influence. Meanwhile, the findings presented in the literature regarding anxiety behaviors induced by animal models of PD have been inconsistent. While some studies suggest the neurotoxin induction of anxiogenic-like behaviors [6, 57, 58] , others reported absence of these effects [13, 59] . Therefore, the present study takes place with this investigation and becomes the first report, to our knowledge, to show the effects of intranigral rotenone in the context of anxietylike behaviors in rats.
Another important point to be examined is the possible sedative effect that could be induced by the MT2 activation. In this regard we did not detect such effect, according to our protocol, as can be seen by the locomotion profile of the 8-M-PDOT treated animals. Interestingly, there is a strong relationship between anxiety disorders and glutamate receptors [60, 61] . In particular, abnormalities in the glutamatergic transmission underlie anxiety [62] . Preclinical data indicate that antagonists of the N-methyl-D-aspartate (NMDA) and group I mGlu receptors reduce anxiety [61, 63] . However, the involvement of glutamate in the neurobiology of anxiety in PD is not yet clear. Another neuropsychiatric condition relevant for PD is depression. It has been demonstrated that melatonin operates as a mediator of the antidepressant-like effects induced by NMDA receptors [64] . Although, more studies about the glutamatergic role of melatonin are needed and this constitutes a very interesting field for futures studies.
Conclusions
Our results demonstrated that the activation of striatal melatonin MT2 receptors elicited anxiolytic-like effects. In opposite, the selective blockade of striatal MT2 receptors, induced by 4-P-PDOT, did not show an anxiogenic-like effect. REMSD was able to induce anxiolytic-like effects similar to 8-M-PDOT. MT2 activation generated a prevalent locomotor increase compared to MT2 blockade in the context of REMSD. Together, these results suggest a striatal MT2 modulation associated to the REMSD-induced dopaminergic supersensitivity causing a possible dopaminergic influence in the MT2 anxiolytic-like effects in the intranigral rotenone model of PD.
